ATE265219T1 - Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten - Google Patents

Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten

Info

Publication number
ATE265219T1
ATE265219T1 AT01931279T AT01931279T ATE265219T1 AT E265219 T1 ATE265219 T1 AT E265219T1 AT 01931279 T AT01931279 T AT 01931279T AT 01931279 T AT01931279 T AT 01931279T AT E265219 T1 ATE265219 T1 AT E265219T1
Authority
AT
Austria
Prior art keywords
cxcr4 antagonists
autoimmune diseases
treat cancer
renewal
self
Prior art date
Application number
AT01931279T
Other languages
English (en)
Inventor
Christopher R Tudan
Ahmed Merzouk
Lakhdar Arab
Geeta Saxena
Connie J Eaves
Johanne Cashman
Ian Clark-Lewis
Hassan Salari
Original Assignee
Univ British Columbia
Chemokine Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002305787A external-priority patent/CA2305787A1/en
Application filed by Univ British Columbia, Chemokine Therapeutics Corp filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE265219T1 publication Critical patent/ATE265219T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01931279T 2000-05-09 2001-05-09 Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten ATE265219T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002305787A CA2305787A1 (en) 2000-05-09 2000-05-09 Cxcr4 antagonist treatment of hematopoietic cells
US20546700P 2000-05-19 2000-05-19
PCT/CA2001/000659 WO2001085196A2 (en) 2000-05-09 2001-05-09 Cxcr4 antagonist treatment of hematopoietic cells

Publications (1)

Publication Number Publication Date
ATE265219T1 true ATE265219T1 (de) 2004-05-15

Family

ID=25681731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01931279T ATE265219T1 (de) 2000-05-09 2001-05-09 Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten

Country Status (6)

Country Link
EP (1) EP1286684B1 (de)
JP (1) JP2003532683A (de)
AT (1) ATE265219T1 (de)
AU (2) AU2001258110B2 (de)
DE (1) DE60103052T2 (de)
WO (1) WO2001085196A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
SI1411918T1 (sl) 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
IL146970A0 (en) * 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
US7521530B2 (en) * 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
ES2403932T3 (es) * 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
JP4781621B2 (ja) * 2002-08-27 2011-09-28 バイオカイン セラピューティックス リミテッド Ｃｘｃｒ４拮抗薬およびその用途
DE10240064A1 (de) * 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
EP1615633B1 (de) * 2003-04-22 2012-08-15 Genzyme Corporation Heterocyclische verbindungen, die sich mit verbesserter wirksamkeit an chemokinrezeptoren binden
MX2007008326A (es) 2005-01-07 2008-01-16 Univ Emory Antagonistas de cxcr4 para el tratamiento de una infeccion por vih.
JP4839032B2 (ja) * 2005-07-13 2011-12-14 国立大学法人 岡山大学 ケモカイン受容体作用増強剤
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2007079460A2 (en) * 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
CN101484151B (zh) * 2006-05-05 2012-11-21 密执安州立大学董事会 二价smac模拟物及其应用
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
US8080659B2 (en) 2006-07-11 2011-12-20 Emory University CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
EP2053060A1 (de) 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-basierte Glycosamingolycan-Antagonisten und Verfahren zu ihrer Verwendung
WO2009074807A2 (en) 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
JP5690715B2 (ja) 2008-03-28 2015-03-25 アルテイリス・セラピユーテイクス ケモカイン受容体調節因子
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
ES2462517T3 (es) * 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
WO2012058241A2 (en) 2010-10-26 2012-05-03 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
KR20200016407A (ko) 2011-05-16 2020-02-14 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
WO2013007704A2 (en) 2011-07-08 2013-01-17 Protaffin Biotechnologie Ag Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
AR087363A1 (es) 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
US10709697B2 (en) 2015-07-16 2020-07-14 Emory University Bis-amines, compositions, and uses related to CXCR4 inhibition
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US9623050B1 (en) * 2016-01-14 2017-04-18 Bio Inventors & Entrepreneur's Network LLC Patient-and condition-specific platelet transfusion support
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
EP3509612A4 (de) * 2016-09-06 2021-07-21 Mainline Biosciences Cxcr4-antagonisten und verfahren zur verwendung
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
CN111683669A (zh) 2017-10-31 2020-09-18 美真达治疗公司 用于造血干细胞和祖细胞移植疗法的组合物和方法
WO2019089826A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
WO2019113375A2 (en) 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (de) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751658B1 (fr) * 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
WO2000009152A1 (en) * 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
EP1189609A4 (de) * 1999-05-03 2002-10-30 Smithkline Beecham Corp Cxcr-4 rezeptor antagonisten und thrombopoietin mimetika

Also Published As

Publication number Publication date
WO2001085196A2 (en) 2001-11-15
AU2001258110B2 (en) 2006-10-19
DE60103052T2 (de) 2005-03-03
AU5811001A (en) 2001-11-20
WO2001085196A3 (en) 2002-02-28
EP1286684A2 (de) 2003-03-05
EP1286684B1 (de) 2004-04-28
JP2003532683A (ja) 2003-11-05
DE60103052D1 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
CR7875A (es) Variantes de inmunoglobina y usos de esto
MX2022012621A (es) Enlazadores de variantes de carga.
HRP20070189A2 (en) Use of erythropoietin
BRPI0412993A (pt) inibidores da atividade da akt
ATE342962T1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
ATE265220T1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
DE60020269D1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
PY0104899A (es) Las 5-alquilpirido [2,3-d] pirimidinas son inhibidoras de las cinasas de tirosina y que dependen de la ciclina
MXPA05011353A (es) Compuestos heterociclicos que se unen al receptor de quimiocina con eficacia mejorada.
ATE245437T1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
BRPI0613770A2 (pt) anticorpos anti-cd26 e métodos de uso destes
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
DE60027768D1 (de) Behandlung von metastatischer krankheit
EA200500871A1 (ru) Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
ATE269340T1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
PT1147103E (pt) Fenantridina-n-oxidos com actividade inibitoria de pde-iv
ATE286074T1 (de) Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
NO20014537L (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties